Compare SBET & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBET | MNKD |
|---|---|---|
| Founded | 1995 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 793.6M |
| IPO Year | 2025 | 2004 |
| Metric | SBET | MNKD |
|---|---|---|
| Price | $7.14 | $2.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $18.71 | $8.56 |
| AVG Volume (30 Days) | ★ 6.3M | 4.6M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | $28,055,000.00 | ★ $348,966,000.00 |
| Revenue This Year | $109.16 | $35.81 |
| Revenue Next Year | $14.66 | $11.89 |
| P/E Ratio | ★ N/A | $131.75 |
| Revenue Growth | ★ 666.04 | 22.23 |
| 52 Week Low | $0.19 | $2.23 |
| 52 Week High | $124.12 | $6.51 |
| Indicator | SBET | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 53.62 | 45.21 |
| Support Level | $6.05 | $2.52 |
| Resistance Level | $8.34 | $4.09 |
| Average True Range (ATR) | 0.38 | 0.12 |
| MACD | 0.07 | 0.12 |
| Stochastic Oscillator | 73.29 | 97.09 |
SharpLink Gaming Inc is one of the world's largest publicly traded companies to adopt ETH as its primary treasury reserve asset - a move that aligns the Company with the future of digital capital and gives investors direct exposure to Ethereum, the world's smart-contract platform and second largest digital asset.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.